Nomlabofusp: Risks & Legal Status

Critical Safety Information#

Nomlabofusp (CTI-1601) is an investigational recombinant fusion protein that has not been approved by any regulatory authority. While it represents a potentially disease-modifying therapy for Friedreich ataxia, several important risks must be considered. All safety information is derived from clinical trials and should be interpreted in the context of limited long-term data and small sample sizes typical of rare disease programs.

Anaphylaxis Risk#

Anaphylaxis is the most clinically significant safety concern identified in the nomlabofusp program:

Incidence#

• 7 participants in the open-label extension study experienced anaphylaxis
• This represents a meaningful incidence rate given the small study population

Timing#

• Most events occurred on the initial day of administration
• All events occurred within the first 6 weeks of dosing
• No late-onset anaphylaxis reported beyond this window

Outcome#

• All 7 affected participants were withdrawn from the study
• All recovered fully with standard anaphylaxis treatment
• No fatal or near-fatal outcomes

Mitigation Strategy#

Larimar Therapeutics implemented a modified starting regimen:

1. 5 mg test dose administered subcutaneously
2. One-hour observation period under medical supervision
3. If tolerated, 25 mg full dose administered
4. Subsequent doses may be self-administered after initial supervised period
5. Patients must have access to epinephrine auto-injector

Context#

Anaphylaxis is a recognized risk with many approved protein therapeutics. The risk profile is comparable to other biologics and is manageable with appropriate precautions, pre-treatment protocols, and patient education.

Investigational Status Risk#

Key uncertainties related to the investigational status:

• Efficacy data are based on surrogate endpoints (frataxin levels) and open-label clinical observations
• No completed randomized controlled trial with clinical outcome primary endpoints
• Long-term safety beyond approximately 18 months of continuous dosing is unknown
• Rare adverse events may emerge with broader use
• Commercial formulation, dosing regimen, and labeling are not finalized

Immunogenicity Risk#

As a recombinant protein administered daily via subcutaneous injection:

• Anti-drug antibodies (ADAs) may develop with chronic exposure
• ADAs could potentially reduce efficacy by neutralizing the fusion protein
• ADAs could increase the risk of hypersensitivity reactions
• Full immunogenicity characterization is ongoing and will be included in the BLA submission
• The anaphylaxis events observed may be related to immune sensitization to the protein

Treatment Burden#

Daily subcutaneous injection represents a significant long-term treatment burden:

• No oral formulation available (protein must be injected)
• Cold chain storage required (2-8 degrees C)
• Treatment interruption leads to loss of frataxin restoration
• Lifelong treatment anticipated given the chronic nature of FA
• Impact on quality of life must be weighed against clinical benefit

Regulatory and Legal Status#

Nomlabofusp is not approved in any country but has received multiple regulatory designations:

Accelerated Approval Pathway#

• FDA has indicated openness to skin frataxin concentration as a surrogate endpoint
• BLA submission planned Q2 2026
• Accelerated approval would require a confirmatory Phase 3 trial
• Global Phase 3 planned as confirmatory study
• US launch targeted for early 2027 if approved

Risk Mitigation#

For Clinical Trial Sites#

1. Administer test dose protocol for all new patients
2. Have anaphylaxis treatment (epinephrine, antihistamines) immediately available
3. Observe patients for minimum 1 hour after initial doses
4. Monitor injection sites for reactions
5. Collect immunogenicity samples per protocol
6. Ensure cold chain integrity for study drug

For Patients in Clinical Trials#

1. Report any signs of allergic reaction immediately
2. Carry epinephrine auto-injector if prescribed
3. Store medication properly (refrigerated, protected from light)
4. Do not skip doses without investigator guidance
5. Attend all scheduled monitoring visits
6. Report any new symptoms promptly

Medical Disclaimer#

This information is provided for educational and research purposes only. Nomlabofusp is an investigational biologic that is not approved for clinical use. No information on this page should be construed as medical advice or a recommendation for treatment. Friedreich ataxia is a serious progressive disease; patients should work with neurologists experienced in FA management to evaluate all available treatment options.

Related Reading#

• Nomlabofusp overview and research guide
• Nomlabofusp side effects profile
• Nomlabofusp research evidence